cilostazol has been researched along with theophylline in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bristol, JA; Cain, MH; Weishaar, RE | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Fujimura, M; Kita, T; Matsuda, T; Myou, S; Tachibana, H | 1 |
| Fujimura, M; Hashimoto, T; Kamio, Y; Matsuda, T; Myou, S | 1 |
| Nagai, H; Tanaka, H; Uno, T | 1 |
| Sawada, M; Suzumura, A; Takayanagi, T; Tamaru, T; Yoshikawa, M | 1 |
| Hasegawa, T; Hiramatsu, K; Ito, Y; Kitaichi, K; Kume, H; Shibata, E; Shimizu, Y; Suzuki, R; Takagi, K; Takeuchi, M; Yamaki, K; Yoshida, N | 1 |
| El Solh, AA; Saliba, R | 1 |
| Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y | 1 |
| Ebihara, S; Ebihara, T; Gui, P; Kohzuki, M; Osaka, K; Sumi, Y | 1 |
| Cho, JG; Jeong, HK; Jin, IT; Lee, KH; Park, HW; Yoon, N | 1 |
4 review(s) available for cilostazol and theophylline
| Article | Year |
|---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Calmodulin; Cardiotonic Agents; Guinea Pigs; Humans; Hypersensitivity; In Vitro Techniques; Lung Diseases; Myocardium; Platelet Aggregation; Substrate Specificity | 1985 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacologic prevention of aspiration pneumonia: a systematic review.
Topics: Aged; Amantadine; Angiotensin-Converting Enzyme Inhibitors; Cabergoline; Capsaicin; Cilostazol; Controlled Clinical Trials as Topic; Ergolines; Humans; Pneumonia, Aspiration; Risk Factors; Sensory System Agents; Tetrazoles; Theophylline | 2007 |
Thermal taste and anti-aspiration drugs: a novel drug discovery against pneumonia.
Topics: Animals; Cilostazol; Drug Discovery; Humans; Pneumonia, Aspiration; Taste; Tetrazoles; Theophylline; Thermoreceptors; Thermosensing | 2014 |
1 trial(s) available for cilostazol and theophylline
| Article | Year |
|---|---|
Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aged; Asthma; Bronchial Hyperreactivity; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Respiratory Function Tests; Tetrazoles; Theophylline | 1997 |
10 other study(ies) available for cilostazol and theophylline
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo.
Topics: Animals; Bronchoconstriction; Bronchodilator Agents; Cilostazol; Dose-Response Relationship, Drug; Guinea Pigs; Histamine; Male; Naphthyridines; Phosphodiesterase Inhibitors; Tetrazoles; Theophylline | 1997 |
Effects of isoenzyme selective phosphodiesterase inhibitors on bacterial lipopolysaccharide-induced bronchial hyperreactivity in guinea pigs.
Topics: Acetylcholine; Animals; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cilostazol; Guinea Pigs; Isoenzymes; Lipopolysaccharides; Male; Neutrophils; Phosphodiesterase Inhibitors; Pyrazines; Pyrrolidinones; Quinolines; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha | 1998 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamole; DNA Primers; Gene Expression Regulation, Enzymologic; Interleukin-1; Interleukin-6; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Papaverine; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Pyrrolidinones; Quinolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha; Vinca Alkaloids; Xanthines | 1999 |
Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.
Topics: Adult; Asthma; Cilostazol; Colforsin; Cyclic AMP; Dexamethasone; Humans; In Vitro Techniques; Interleukin-13; Kinetics; Leukocytes, Mononuclear; Male; Phosphodiesterase Inhibitors; Phytohemagglutinins; Rolipram; Tetrazoles; Theophylline | 2001 |
Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels.
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Decanoic Acids; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Hydroxy Acids; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Potassium Channel Blockers; Purinergic P1 Receptor Antagonists; Rabbits; Reperfusion Injury; Superoxides; Tetrazoles; Theophylline | 2011 |
Positive chronotropic effects of theophylline and cilostazol in patients with symptomatic sick sinus syndrome who have declined permanent pacing.
Topics: Aged; Cardiac Pacing, Artificial; Cardiovascular Agents; Cilostazol; Drug Substitution; Female; Heart Rate; Humans; Male; Middle Aged; Recovery of Function; Retrospective Studies; Sick Sinus Syndrome; Theophylline; Time Factors; Treatment Outcome; Treatment Refusal | 2020 |